The Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent agency funded by Canadian federal, provincial, and territorial governments to provide health care decision makers with credible, impartial advice and information about the effectiveness and efficiency of drugs and other health technologies. Unlike regulators who determine which technologies can be used in Canada, CADTH supports decision makers who are exploring what technologies should be used to achieve the best outcomes both on patient health and the health care system.
December 7, 2009
A new online continuing medical education (CME) course is available entitled “PPIs and the Treatment of GERD, Dyspepsia and NSAID-associated Peptic Ulcer Disease.”
The course was developed by MDcme.ca using CADTH’s series of Optimal Therapy Reports on proton pump inhibitors (PPIs), including clinical and cost-effectiveness evidence and recommendations for optimal prescribing and use. The launch of this course is the latest example of how CADTH provides stakeholders with credible, evidence-based information that supports patient care and the effective use of health care resources.
The aim of the course is to increase awareness among physicians and other health care practitioners of the optimal use of PPIs in the management of upper gastrointestinal conditions. The course is available free of charge to registered users of MDcme.ca and has been accredited for MainPro M1 for up to 1.5 credit hours.
Following completion of the course, learners should be able to:
Visit the PPI section of CADTH’s website for complete information about the PPI topic, including scientific reports and tools to help decision-makers put evidence into practice.